Financials in USD. Standardized financial statements.
A compact view of how NewGenIvf Group Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue? | $4.73M | $5.43M | $5.14M | $5.94M | $4.12M |
| Revenue Growth? | -13.0% | +5.8% | -13.6% | +44.3% | 0.0% |
| Cost of Revenue? | $3.77M | $3.61M | $3.45M | $4.41M | $3.09M |
| Gross Profit? | $955,846 | $1.83M | $1.68M | $1.54M | $1.02M |
| Gross Margin? | +20.2% | +33.6% | +32.7% | +25.9% | +24.9% |
| Operating Expenses? | $11.68M | $2.99M | $1.64M | $1.14M | $826,022 |
| Operating Income? | -$10.73M | -$1.16M | $42,242 | -$504,907 | $198,758 |
| EBITDA? | $10.84M | $24,264 | $384,308 | $725,689 | $587,012 |
| Income Before Tax | $9.73M | -$961,000 | $108,418 | $500,650 | $156,184 |
| Income Tax Expense | $0 | -$487,000 | $0 | $208,141 | $294,716 |
| Net Income? | $9.88M | -$525,000 | $130,193 | $458,667 | -$533 |
| EPS? | $16.80 | $-22.31 | $12.44 | $62.52 | $-0.00 |
| Diluted EPS? | $16.80 | $-22.31 | $12.44 | $62.52 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality